Recro Pharma (REPH) Announces Dosing Of First Patient In Phase 2b Clinical Trial Of Dex-IN For Treatment Of Acute Pain Following Surgery
6/17/2014 8:51:16 AM
MALVERN, Pa., June 17, 2014 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery, today announced dosing of the first patient in a Phase IIb clinical trial of Dex-IN in patients undergoing bunionectomy surgery.
Help employers find you! Check out all the jobs and post your resume.
comments powered by